Nomigrin (Naproxen Sodium, Sumatriptan Succinate)

Naproxen sodium and sumatriptan succinate, the active ingredients in Nomigrin, are a NSAID and 5‑HT1B/1D agonist combination presented as an oral tablet for oral use. It treats acute migraine attacks in adult patients who need rapid relief of headache and associated symptoms.

GNH USA supplies Nomigrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nomigrin is indicated for the acute treatment of migraine and related headache disorders. - Acute migraine: provides rapid relief of moderate to severe headache pain and associated nausea. - Migraine with aura: alleviates both the headache phase and visual or sensory aura symptoms. - Severe migraine attacks: reduces the need for rescue medication and improves functional ability. - Refractory migraine episodes: offers an alternative when single‑agent therapy has been insufficient. - Migraine in adults: approved for patients aged 18 years and older seeking prompt symptom control.

The following adverse reactions have been reported with the naproxen sodium/sumatriptan combination.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Dry mouth: reduced salivation. - Fatigue: feeling of tiredness. - Tingling sensation: paresthesia in extremities. - Upper abdominal discomfort: mild pain.

Serious or Rare Side Effects: - Chest pain or tightness: possible cardiac ischemia. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperthermia, or muscle rigidity when combined with serotonergic drugs. - Cardiovascular events: stroke or myocardial infarction. - Severe abdominal pain: possible gastrointestinal ulceration or bleeding. - Elevated liver enzymes: indication of hepatic stress.

Before prescribing Nomigrin, clinicians should consider the following safety measures. - Cardiovascular assessment: evaluate history of ischemic heart disease or uncontrolled hypertension. - Hepatic function: use caution in patients with liver impairment. - Renal function: adjust use in severe renal insufficiency. - Serotonergic drugs: monitor for signs of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nomigrin may interact with several medication classes; awareness of the interaction level helps guide therapy.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstriction leading to cardiovascular events. - SSRIs, SNRIs, or other serotonergic agents: increased chance of serotonin syndrome. - Anticoagulants (e.g., warfarin): heightened bleeding risk due to naproxen's antiplatelet effect.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may raise naproxen plasma levels. - Antihypertensive agents: possible attenuation of blood‑pressure‑lowering effect. - Additional NSAIDs: increased gastrointestinal toxicity. - Diuretics: potential reduction in renal clearance of naproxen.